Akribion Genomics receives the Hessian Founder Award for its innovative approach to a new cancer therapy

BRAIN Biotech AG’s Akribion Genomics technology receives patent approval for its groundbreaking nuclease G-dase E®

BRAIN Biotech AG Scientist receives VAAM Innovation Award for the discovery of a novel CRISPR nuclease family

Akribion Genomics successfully competes in Science4Life Venture Cup competition

Incubator: Akribion Genomics to focus on opportunities in therapeutics

BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment

BRAIN Group’s Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform.

Change in the Executive Management Board of BRAIN Biotech AG, genome editing activities established under the Akribion Genomics brand.